Alps Advisors Inc Aclaris Therapeutics, Inc. Transaction History

Alps Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.56 - $10.95 $1,764 - $2,945	269 Added 0.52%	52,222 $357,000
Q2 2023 Aug 14, 2023	BUY	$7.89 - $10.64 $63,254 - $85,300	8,017 Added 18.25%	51,953 $538,000
Q1 2023 May 10, 2023	SELL	$7.07 - $17.95 $8,971 - $22,778	-1,269 Reduced 2.81%	43,936 $355,000
Q4 2022 Feb 14, 2023	BUY	$14.33 - $18.37 $647,787 - $830,415	45,205 New	45,205 $711,000
Q4 2018 Feb 04, 2019	SELL	$6.3 - $15.4 $345,391 - $844,289	-54,824 Closed	0 $0
Q3 2018 Oct 25, 2018	BUY	$14.38 - $20.89 $143,469 - $208,419	9,977 Added 22.25%	54,824 $796,000
Q2 2018 Aug 02, 2018	BUY	$16.46 - $20.33 $175,776 - $217,104	10,679 Added 31.25%	44,847 $896,000
Q2 2018 Jul 25, 2018	SELL	$16.46 - $20.33 $118,528 - $146,396	-7,201 Reduced 17.41%	34,168 $843,000
Q1 2018 May 01, 2018	BUY	$17.08 - $25.64 $122,993 - $184,633	7,201 Added 21.08%	41,369 $725,000
Q4 2017 Feb 05, 2018	BUY	$21.47 - $27.8 $99,320 - $128,602	4,626 Added 15.66%	34,168 $843,000
Q3 2017 Nov 03, 2017	BUY	$23.02 - $28.8 $680,056 - $850,809	29,542	29,542 $762,000

50.7M

30.6K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $253M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.